SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event

被引：3
|
作者：
Tukker, Martijn [1 ]
Bruwiere, Ewout [1 ]
Bos, Sven [2 ]
Caliskan, Kadir [1 ,3 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Thoraxctr, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Haematol, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Room RG 431,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
来源：
CIRCULATION-HEART FAILURE | 2023年 / 16卷 / 07期
关键词：
adverse drug event; dapagliflozin; erythrocytosis; heart failure; polycythemia;
D O I：
10.1161/CIRCHEARTFAILURE.123.010613
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
According to the current heart failure guidelines, SGLT2 (sodium glucose cotransporter 2) inhibitors are increasingly prescribed in patients with heart failure (HF).1 However, SGLT2-inhibitors are known to increase hemoglobin (Hb) and hematocrit (Ht) levels, but literature on SGLT2-induced erythrocytosis is limited. We provide a case of a patient with chronic HF with severe polycythemia associated with dapagliflozin usage, suggesting the potential importance of hemoglobin and hematocrit monitoring. © 2023 Lippincott Williams and Wilkins. All rights reserved.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failure
    Pietschner, R.
    Kolwelter, J.
    Bosch, A.
    Kannenkeril, D.
    Ott, C.
    Schiffer, M.
    Achenbach, S.
    Schmieder, R. E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 107 - 107
  • [42] Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
    Cheng, Judy W. M.
    Colucci, Vincent
    Kalus, James S.
    Spinler, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (02) : 252 - 260
  • [43] SGLT2 inhibitors - New treatment options for chronic kidney disease and heart failure
    Eliasdottir, Sigriour Birna
    LAEKNABLADID, 2024, 110 (12): : 558 - 563
  • [44] Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
    Pabel, Steffen
    Hamdani, Nazha
    Singh, Jagdeep
    Sossalla, Samuel
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [45] Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
    Galli, Mattia
    D'Amario, Domenico
    Sofia, Carmelo
    Vaccarella, Marcello
    Crea, Filippo
    Aspromonte, Nadia
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (12) : 1273 - 1285
  • [46] Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series
    Meier, Mackenzi
    Ansong, Benedicta
    Awobusuyi, Dolapo
    Lee-Oyagha, Raven
    Lopez, Sarah
    JOURNAL OF PHARMACY PRACTICE, 2025, 38 (01) : 193 - 197
  • [47] Circulating ketone bodies in patients with acute heart failure treated with the SGLT2 inhibitor empagliflozin
    Voorrips, S. N.
    Boorsma, E. M.
    Beusekamp, J. C.
    De Boer, R. A.
    Connelly, M. A.
    Dullaart, R. P. F.
    Van Der Meer, P.
    Van Veldhuisen, D. J.
    Voors, A. A.
    Damman, K.
    Westenbrink, B. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 195 - 196
  • [48] SGLT2 INHIBITOR PRESCRIPTION RATE FOR PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
    Kim, Justin
    Chakrala, Teja
    Prakash, Roshni
    Ghaffar, Umar
    Patel, Jaymin
    Dass, Bhagwan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 404 - 404
  • [49] Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Kulac, Ian J.
    Miao, Zi Michael
    Desai, Akshay S.
    Jhund, Pardeep S.
    Henderson, Alasdair D.
    Brinker, Meike
    Lay-Flurrie, James
    Viswanathan, Prabhakar
    Scheerer, Markus Florian
    Lage, Andrea
    Lam, Carolyn S. P.
    Senni, Michele
    Shah, Sanjiv J.
    Voors, Adriaan A.
    Zannad, Faiez
    Pitt, Bertram
    Mcmurray, John J. V.
    Solomon, Scott D.
    CIRCULATION, 2025, 151 (02) : 149 - 158
  • [50] Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
    Selvaraj, Senthil
    Patel, Shachi
    Sauer, Andrew J.
    Mcgarrah, Robert W.
    Jones, Philip
    Kwee, Lydia Coulter
    Windsor, Sheryl L.
    Ilkayeva, Olga
    Muehlbauer, Michael J.
    Newgard, Christopher B.
    Borlaug, Barry A.
    Kitzman, Dalane W.
    Shah, Sanjiv J.
    Margulies, Kenneth B.
    Husain, Mansoor
    Inzucchi, Silvio E.
    Mcguire, Darren K.
    Lanfear, David E.
    Javaheri, Ali
    Umpierrez, Guillermo
    Mentz, Robert J.
    Sharma, Kavita
    Kosiborod, Mikhail N.
    Shah, Svati H.
    CIRCULATION-HEART FAILURE, 2024, 17 (11)
12345